Cargando…

The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial

The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose, we measured selected molecules (N-epsilon-carboxy methyl lysine (CML), laminin P1 (Lam-P1), and asymmetric dimethylargin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández, Cristina, Porta, Massimo, Bandello, Francesco, Grauslund, Jakob, Harding, Simon P., Aldington, Stephen J., Egan, Catherine, Frydkjaer-Olsen, Ulrik, García-Arumí, José, Gibson, Jonathan, Lang, Gabriele E., Lattanzio, Rosangela, Massin, Pascale, Midena, Edoardo, Ponsati, Berta, Ribeiro, Luísa, Scanlon, Peter, Cunha-Vaz, José, Simó, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231127/
https://www.ncbi.nlm.nih.gov/pubmed/32344735
http://dx.doi.org/10.3390/jcm9041233
_version_ 1783535119279063040
author Hernández, Cristina
Porta, Massimo
Bandello, Francesco
Grauslund, Jakob
Harding, Simon P.
Aldington, Stephen J.
Egan, Catherine
Frydkjaer-Olsen, Ulrik
García-Arumí, José
Gibson, Jonathan
Lang, Gabriele E.
Lattanzio, Rosangela
Massin, Pascale
Midena, Edoardo
Ponsati, Berta
Ribeiro, Luísa
Scanlon, Peter
Cunha-Vaz, José
Simó, Rafael
author_facet Hernández, Cristina
Porta, Massimo
Bandello, Francesco
Grauslund, Jakob
Harding, Simon P.
Aldington, Stephen J.
Egan, Catherine
Frydkjaer-Olsen, Ulrik
García-Arumí, José
Gibson, Jonathan
Lang, Gabriele E.
Lattanzio, Rosangela
Massin, Pascale
Midena, Edoardo
Ponsati, Berta
Ribeiro, Luísa
Scanlon, Peter
Cunha-Vaz, José
Simó, Rafael
author_sort Hernández, Cristina
collection PubMed
description The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose, we measured selected molecules (N-epsilon-carboxy methyl lysine (CML), laminin P1 (Lam-P1), and asymmetric dimethylarginine (ADMA)) in the serum of 341 participants of the EUROCONDOR study at baseline, 24, and 48 weeks. Retinal neurodysfunction was assessed by measuring implicit time (IT) using multifocal electroretinography, and structural changes were examined by spectral domain–optical coherence tomography. The values of IT at baseline were directly correlated with baseline serum concentrations of CML (r = 0.135, p = 0.013). Furthermore, in the placebo group, increase in CML concentration throughout follow-up correlated with the IT (r = 0.20; p = 0.03). Baseline serum levels of CML also correlated with macular retinal thickness (RT) (r = 0.231; p < 0.001). Baseline Lam-P1 levels correlated with the increase of the RT at the end of follow-up in the placebo group (r = 0.22; p = 0.016). We provide evidence that CML may be a biomarker of both retinal neurodysfunction and RT, whereas Lam-P1 was associated with RT only. Therefore, circulating levels of these molecules could provide a complementary tool for monitoring the early changes of diabetic retinopathy (DR).
format Online
Article
Text
id pubmed-7231127
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72311272020-05-22 The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial Hernández, Cristina Porta, Massimo Bandello, Francesco Grauslund, Jakob Harding, Simon P. Aldington, Stephen J. Egan, Catherine Frydkjaer-Olsen, Ulrik García-Arumí, José Gibson, Jonathan Lang, Gabriele E. Lattanzio, Rosangela Massin, Pascale Midena, Edoardo Ponsati, Berta Ribeiro, Luísa Scanlon, Peter Cunha-Vaz, José Simó, Rafael J Clin Med Article The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose, we measured selected molecules (N-epsilon-carboxy methyl lysine (CML), laminin P1 (Lam-P1), and asymmetric dimethylarginine (ADMA)) in the serum of 341 participants of the EUROCONDOR study at baseline, 24, and 48 weeks. Retinal neurodysfunction was assessed by measuring implicit time (IT) using multifocal electroretinography, and structural changes were examined by spectral domain–optical coherence tomography. The values of IT at baseline were directly correlated with baseline serum concentrations of CML (r = 0.135, p = 0.013). Furthermore, in the placebo group, increase in CML concentration throughout follow-up correlated with the IT (r = 0.20; p = 0.03). Baseline serum levels of CML also correlated with macular retinal thickness (RT) (r = 0.231; p < 0.001). Baseline Lam-P1 levels correlated with the increase of the RT at the end of follow-up in the placebo group (r = 0.22; p = 0.016). We provide evidence that CML may be a biomarker of both retinal neurodysfunction and RT, whereas Lam-P1 was associated with RT only. Therefore, circulating levels of these molecules could provide a complementary tool for monitoring the early changes of diabetic retinopathy (DR). MDPI 2020-04-24 /pmc/articles/PMC7231127/ /pubmed/32344735 http://dx.doi.org/10.3390/jcm9041233 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hernández, Cristina
Porta, Massimo
Bandello, Francesco
Grauslund, Jakob
Harding, Simon P.
Aldington, Stephen J.
Egan, Catherine
Frydkjaer-Olsen, Ulrik
García-Arumí, José
Gibson, Jonathan
Lang, Gabriele E.
Lattanzio, Rosangela
Massin, Pascale
Midena, Edoardo
Ponsati, Berta
Ribeiro, Luísa
Scanlon, Peter
Cunha-Vaz, José
Simó, Rafael
The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
title The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
title_full The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
title_fullStr The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
title_full_unstemmed The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
title_short The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
title_sort usefulness of serum biomarkers in the early stages of diabetic retinopathy: results of the eurocondor clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231127/
https://www.ncbi.nlm.nih.gov/pubmed/32344735
http://dx.doi.org/10.3390/jcm9041233
work_keys_str_mv AT hernandezcristina theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT portamassimo theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT bandellofrancesco theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT grauslundjakob theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT hardingsimonp theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT aldingtonstephenj theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT egancatherine theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT frydkjaerolsenulrik theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT garciaarumijose theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT gibsonjonathan theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT langgabrielee theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT lattanziorosangela theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT massinpascale theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT midenaedoardo theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT ponsatiberta theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT ribeiroluisa theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT scanlonpeter theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT cunhavazjose theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT simorafael theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT hernandezcristina usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT portamassimo usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT bandellofrancesco usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT grauslundjakob usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT hardingsimonp usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT aldingtonstephenj usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT egancatherine usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT frydkjaerolsenulrik usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT garciaarumijose usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT gibsonjonathan usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT langgabrielee usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT lattanziorosangela usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT massinpascale usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT midenaedoardo usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT ponsatiberta usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT ribeiroluisa usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT scanlonpeter usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT cunhavazjose usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial
AT simorafael usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial